Genelux Corp. (GNLX)
NASDAQ:GNLX
Want to see GNLX full AI Analyst Report?
GNLX Stock Chart & Stats
$2.79
-$0.06(-2.24%)
At close: 4:00 PM EST
$2.79
-$0.06(-2.24%)
Day’s Range― - ―
52-Week Range$2.29 - $8.54
Previous CloseN/A
Volume23.79K
Average Volume (3M)156.94K
Market Cap
$132.73M
Enterprise Value$107.95M
Total Cash (Recent Filing)$26.21M
Total Debt (Recent Filing)$2.50M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Aug 18, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.88
Shares Outstanding44,840,416
10 Day Avg. Volume178,540
30 Day Avg. Volume156,945
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)14.04
Price to Sales (P/S)20261.21
P/FCF Ratio-6.15
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue13.49K
Enterprise Value/Gross Profit-380.12
Enterprise Value/Ebitda-3.37
Forecast
1Y Price Target
$19.75Price Target Upside607.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.82
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Oncolytic Vaccinia PlatformGenelux's proprietary oncolytic vaccinia platform and lead candidates (GEN-1, GEN-2) provide a durable technological moat in oncolytic immunotherapy. If clinical data validate mechanism, platform enables multiple tumor indications, partnerships, and product-line leverage beyond a single asset.
Low Financial LeverageModest reported debt versus equity implies low financial leverage relative to peers, reducing bankruptcy risk and interest burden. This balance-sheet strength improves strategic optionality to invest in trials or seek partnerships without immediate creditor pressure over the next several months.
Established $100M ATM Financing ProgramThe $100M ATM program creates a durable capital-raising mechanism that can be tapped proactively to fund R&D and trials. By providing flexible access to equity markets, management can extend runway and pace clinical programs without needing one-time dilutive financings tied to immediate cash shortfalls.
Bears Say
High Cash Burn And Negative Free Cash FlowSustained multi‑million dollar negative operating and free cash flow indicates the company cannot self-fund development. Persistent burn forces frequent external raises, compresses strategic choices, and may require slowing or reprioritizing programs if capital access tightens over the next several quarters.
Minimal Recurring RevenueWith essentially no product revenue, the business model remains fully development‑stage and dependent on clinical milestones. Long-term sustainability hinges on successful trials and commercialization, making current operations vulnerable to setbacks and prolonging reliance on non‑operational funding sources.
Dependence On External Financing And Dilution RiskThe company's reliance on equity financings and the new ATM increases shareholder dilution risk and ties strategic pacing to market access. Repeated raises can dilute long‑term returns and create execution uncertainty if investor appetite weakens during clinical readout cycles over the next 2–6 months.
Genelux Corp. News
GNLX FAQ
What was Genelux Corp.’s price range in the past 12 months?
Genelux Corp. lowest stock price was $2.29 and its highest was $8.54 in the past 12 months.
What is Genelux Corp.’s market cap?
Genelux Corp.’s market cap is $132.73M.
When is Genelux Corp.’s upcoming earnings report date?
Genelux Corp.’s upcoming earnings report date is Aug 18, 2026 which is in 64 days.
How were Genelux Corp.’s earnings last quarter?
Genelux Corp. released its earnings results on May 13, 2026. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.195 by -$0.005.
Is Genelux Corp. overvalued?
According to Wall Street analysts Genelux Corp.’s price is currently Undervalued.
Does Genelux Corp. pay dividends?
Genelux Corp. does not currently pay dividends.
What is Genelux Corp.’s EPS estimate?
Genelux Corp.’s EPS estimate is -0.2.
How many shares outstanding does Genelux Corp. have?
Genelux Corp. has 44,840,416 shares outstanding.
What happened to Genelux Corp.’s price movement after its last earnings report?
Genelux Corp. reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.195. Following the earnings report the stock price went up 7.407%.
Which hedge fund is a major shareholder of Genelux Corp.?
Currently, no hedge funds are holding shares in GNLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genelux Corp. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.75 (607.89% Upside)
$19.75 (607.89% Upside)
Hedge Fund Trend
Decreased
By 631.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $27.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
136.72%
12-Months-Change
Fundamentals
Return on Equity
-165.18%
Trailing 12-Months
Asset Growth
-16.96%
Trailing 12-Months
Company Description
Genelux Corp.
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
GNLX Stock 12 Month Forecast
Average Price Target
$19.75
▲(607.89% Upside)
Technical Analysis
Coherus Biosciences
―
Fate Therapeutics
―
Tonix Pharma
―
Corbus Pharmaceuticals
―
Forte Biosciences
―
Ownership Overview
3.55% Insiders
4.66% Mutual Funds
10.90% Other Institutional Investors
76.95% Public Companies and
Individual Investors